Systematic analysis identifies TRIM22 as an oncogenic and immunological biomarker in glioma. Hu Y, Zhi H, Zhang A, Lu S, et al. BMC Cancer 2025;25:1202.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hu Y, Zhi H, Zhang A, Lu S, et al. Systematic analysis identifies TRIM22 as an oncogenic and immunological biomarker in glioma. BMC Cancer 2025;25:1202.
PMID: 40702424